Makary M A, Warshaw A L, Centeno B A, Willet C G, Rattner D W, Fernández-del Castillo C
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
Arch Surg. 1998 Apr;133(4):361-5. doi: 10.1001/archsurg.133.4.361.
To assess the implications of positive cytology for malignant cells (positive results) from peritoneal washings in the management of patients with pancreatic cancer.
Retrospective cohort study.
Referral practice in a university hospital.
A total of 32 consecutive pancreatic cancer patients with positive results from peritoneal washings during a 4-year period, 17 with visible biopsy-proven intraabdominal metastases at the time of laparoscopy or laparotomy and 15 without visible metastases. A treatment-matched control group of 30 patients was randomly selected from a group of 105 patients with negative cytology for malignant cells (negative results) from peritoneal-fluid cytology.
Eight of 17 patients with visible metastases underwent treatment with chemotherapy, radiation, or both; 13 of the 15 patients with no visible metastases underwent further treatment, including pancreatic resection in 2 patients and external beam radiation in 13 patients (3 with intraoperative radiation therapy).
Time to metastases and mortality.
Median survival among patients with and without visible metastasis was 7.8 months and 8.6 months, respectively (P=.95), despite the fact that patients without visible metastases received more treatment. Patients without visible metastases at presentation were found to have metastatic disease as documented by computed tomographic scan or subsequent laparotomy at a median time of 2.9 months. The survival of treatment-matched patients with negative cytology was significantly longer (median, 13.5 months; P=.04).
Pancreatic cancer patients with peritoneal micrometastases have a dismal outcome even without macroscopic metastases. Since these patients do not benefit from local therapy, the finding of a positive result from peritoneal-fluid cytologic testing contraindicates further irradiation or surgery, except for specific complications.
评估胰腺癌患者腹膜灌洗中恶性细胞细胞学检查呈阳性(阳性结果)对患者治疗的影响。
回顾性队列研究。
大学医院的转诊机构。
4年间共有32例胰腺癌患者腹膜灌洗结果呈阳性,其中17例在腹腔镜检查或剖腹手术时经活检证实有肉眼可见的腹腔内转移,15例无肉眼可见转移。从105例腹膜液细胞学检查恶性细胞呈阴性(阴性结果)的患者中随机选取30例作为治疗匹配的对照组。
17例有肉眼可见转移的患者中有8例接受了化疗、放疗或两者联合治疗;15例无肉眼可见转移的患者中有13例接受了进一步治疗,其中2例行胰腺切除术,13例行外照射放疗(3例术中放疗)。
发生转移的时间和死亡率。
有肉眼可见转移和无肉眼可见转移患者的中位生存期分别为7.8个月和8.6个月(P = 0.95),尽管无肉眼可见转移的患者接受了更多治疗。初诊时无肉眼可见转移的患者经计算机断层扫描或随后的剖腹手术证实,中位2.9个月时出现转移性疾病。治疗匹配的细胞学检查阴性患者的生存期明显更长(中位生存期13.5个月;P = 0.04)。
即使没有宏观转移,有腹膜微转移的胰腺癌患者预后也很差。由于这些患者无法从局部治疗中获益,因此腹膜液细胞学检查呈阳性表明除特定并发症外,禁忌进一步放疗或手术。